Insmed Valuation
Is INSM * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of INSM * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: INSM * (MX$488.51) is trading below our estimate of fair value (MX$3537.53)
Significantly Below Fair Value: INSM * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for INSM *?
Key metric: As INSM * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is INSM *'s PS Ratio? | |
|---|---|
| PS Ratio | 12.5x |
| Sales | US$305.21m |
| Market Cap | US$3.82b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 14.4x |
| Enterprise Value/EBITDA | -6.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does INSM *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.4x | ||
LAB B Genomma Lab Internacional. de | 1.4x | 9.9% | Mex$24.9b |
301301 Yili Chuanning BiotechnologyLtd | 5.1x | 10.0% | CN¥28.5b |
PTCT PTC Therapeutics | 3.7x | 5.5% | US$3.3b |
688278 Xiamen Amoytop Biotech | 11.4x | 29.0% | CN¥29.2b |
INSM * Insmed | 12.5x | 34.6% | Mex$3.8b |
Price-To-Sales vs Peers: INSM * is expensive based on its Price-To-Sales Ratio (12.5x) compared to the peer average (8.2x).
Price to Sales Ratio vs Industry
How does INSM *'s PS Ratio compare vs other companies in the Global Biotechs Industry?
| 278 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 278 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: INSM * is expensive based on its Price-To-Sales Ratio (12.5x) compared to the Global Biotechs industry average (10.8x).
Price to Sales Ratio vs Fair Ratio
What is INSM *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 12.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate INSM *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
ICON
US$17.7b
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
ICLR N
US$4,286.08
7D
0%
1Y
-7.7%
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a